报告显示，在59例可评价的的患者中有25%的患者在8周的贝伐单抗（bevacizumab，Avastin）加厄洛替尼（erlotinib，Tarceva）治疗后显示客观缓解，有61%的患者显示疾病稳定。在该研究中有63例转移性肾透明细胞癌患者接受贝伐单抗10mg/kg，每2周1次静脉注射，加厄洛替尼150mg每日1次的治疗。8周时研究者对患者进行了评价、显示缓解的患者将继续治疗。结果显示，8周时有8例患者显示疾病进展。中位生存期为11个月，其中43%的患者在生存1年时显示无疾病进展，以及18个月时仍有60%的患者存活。最常见的副作用是腹泻、皮疹，其中2例患者因皮疹停止治疗。
研究者在结论中表示将进一步进行其他标靶药物联合治疗肾细胞癌的研究。
J Clin Oncol. 2005 Nov 1;23(31):7889-96.
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A.
Sarah Cannon Research Institute, Nashville, TN 37203, USA.
PURPOSE: To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma. PATIENTS AND METHODS: Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally daily. Patients were reevaluated after 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progression. RESULTS: Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective responses to treatment, and an additional 36 patients (61%) had stable disease after 8 weeks of treatment. Only eight patients'''' (14%) disease had progressed at this time point. The median and 1-year progression-free survivals were 11 months and 43%, respectively. After a median follow-up of 15 months, median survival has not been reached; survival at 18 months was 60%. Treatment was generally well tolerated; only two patients discontinued treatment because of toxicity (skin rash). Grade 1/2 skin rash and diarrhea were the most frequent treatment-related toxicities. CONCLUSION: The combination of bevacizumab and erlotinib is an effective and well-tolerated treatment for patients with advanced renal cell carcinoma. The efficacy of these two drugs in combination suggests that targeting of separate pathways critical to tumor growth and dissemination may achieve results superior to either drug as a single agent. Additional development of this and other combinations of targeted agents is warranted.
Publication Types:
• Clinical Trial, Phase II
• Multicenter Study
PMID: 16204015 [PubMed - indexed for MEDLINE]
Copyright Status
Government information available from this site is within the public domain. Public domain information on the National Library of Medicine (NLM) Web pages may be freely distributed and copied. However, it is requested that in any subsequent use of this work, NLM be given appropriate acknowledgment.
This site also contains resources such as PubMed Central, Bookshelf, OMIM, and PubChem which incorporate material contributed or licensed by individuals, companies, or organizations that may be protected by U.S. and foreign copyright laws. All persons reproducing, redistributing, or making commercial use of this information are expected to adhere to the terms and conditions asserted by the copyright holder. Transmission or reproduction of protected items beyond that allowed by fair use (PDF) as defined in the copyright laws requires the written permission of the copyright owners.
2006-3-15
| 药品价格(单位:元) | ||||||
|
编号 |
药品名称 |
通用名 |
产地 |
规格 |
单位 |
参考价 |
| 121809 | 特罗凯 | 盐酸厄洛替尼片 | Schwarz Pharma Manufacturing Inc. | 150mg*30片 | 盒 | 18500 |
| *声明：以上价格仅作参考,实际价格以药房各分店为准。 | ||||||